Get the Stockscreener App
0.7681
1.05%
0.008
Pre-market:
.77
0.0019
+0.25%
Rani Therapeutics Holdings Inc stock is traded at $0.7681, with a volume of 791.83K.
It is up +1.05% in the last 24 hours and down -28.88% over the past month.
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.
See More
Previous Close:
$0.7601
Open:
$0.8
24h Volume:
791.83K
Relative Volume:
0.71
Market Cap:
$86.33M
Revenue:
$3.17M
Net Income/Loss:
$-36.23M
P/E Ratio:
-1.8789
EPS:
-0.4088
Net Cash Flow:
$-17.11M
1W Performance:
-8.52%
1M Performance:
-28.88%
6M Performance:
-47.03%
1Y Performance:
+46.22%
1-Day Range:
$0.7604
$0.81
1-Week Range:
$0.76
$0.8501
52-Week Range:
$0.387
$3.87
Rani Therapeutics Holdings Inc Stock (RANI) Company Profile
Name
Rani Therapeutics Holdings Inc
Sector
Industry
Phone
(408) 457-3700
Address
2051 RINGWOOD AVENUE, SAN JOSE
Compare RANI vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RANI
Rani Therapeutics Holdings Inc
|
0.7681 | 86.33M | 3.17M | -36.23M | -17.11M | -0.4088 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Rani Therapeutics Holdings Inc Stock (RANI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-14-26 | Initiated | Lake Street | Buy |
| Aug-02-24 | Initiated | Oppenheimer | Outperform |
| Jun-14-24 | Initiated | Maxim Group | Buy |
| Jun-13-24 | Initiated | Rodman & Renshaw | Buy |
| Apr-17-23 | Resumed | BTIG Research | Buy |
| Oct-11-22 | Initiated | UBS | Buy |
| Jul-27-22 | Initiated | H.C. Wainwright | Buy |
| Jun-13-22 | Initiated | Wedbush | Outperform |
View All
Rani Therapeutics Holdings Inc Stock (RANI) Latest News
RANI Stock Price, Quote & Chart - ChartMill
RANI Stock Price and Chart — NASDAQ:RANI - TradingView
Rani Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Javadi Alireza - Moomoo
[Form 4] Rani Therapeutics Holdings, Inc. Insider Trading Activity - Stock Titan
Rani Therapeutics (RANI) grants CBO 805,500 stock options - Stock Titan
Rani Therapeutics (NASDAQ: RANI) CTO awarded 805,500 stock options - Stock Titan
Rani Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director IMRAN MIR A - Moomoo
Rani Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Ausiello Dennis A - Moomoo
Director Abraham Bassan receives 123,600 Rani (RANI) stock options - Stock Titan
Rani Therapeutics (NASDAQ: RANI) director receives stock options on 123,600 shares - Stock Titan
Imran Mir A of Rani Therapeutics (NASDAQ: RANI) receives 123,600 stock options - Stock Titan
Director at Rani Therapeutics (RANI) receives 123,600 stock options as compensation award - Stock Titan
Rani Therapeutics (RANI) director granted 123,600 options at $0.9515 exercise price - Stock Titan
Rani Therapeutics (RANI) director receives 123,600 stock options at $0.9515 strike - Stock Titan
Rani Therapeutics | 8-K: Current report - Moomoo
Rani Therapeutics (RANI) stockholders elect directors and ratify 2026 auditor - Stock Titan
Akkaraju funds lift Rani Therapeutics (RANI) beneficial stake to 9.99% - Stock Titan
Rani Therapeutics to raise $20M in registered direct offering - MSN
Rani Therapeutics | 424B5: Prospectus - Moomoo
Rani Therapeutics Holdings, Inc. Announces Securities Purchase Agreement and Pre-Funded Warrant Offering – SEC 8-K Filing Details - Minichart
Rani Therapeutics (RANI) raises ~$19.99M via Class A shares and pre-funded warrants - Stock Titan
Rani Therapeutics to Raise ~$20M via $1.07 Share Offering and Pre-Funded Warrants - TradingView
Rani Therapeutics (RANI) prices $20M stock and pre-funded warrant sale - Stock Titan
Rani Therapeutics Prices Registered Direct Offering of 12.5 Million Shares - Moomoo
Rani Therapeutics prices $20M direct offering of Class A common stock at market price - Pluang
Rani Therapeutics raises $20 million in direct offering By Investing.com - Investing.com Nigeria
Rani Therapeutics raises $20 million in direct offering - Investing.com
Rani Therapeutics Holdings, Inc. Announces Pricing of $20.0 Million Registered Direct Offering of Class A Common Stock Priced At-The-Market Under Nasdaq Rules - The Manila Times
Rani Therapeutics Holdings, Inc. Announces Pricing of $20.0 - GlobeNewswire
Rani Therapeutics Holdings (RANI) price target decreased by 12.50% to 7.14 - MSN
Maxim Group Maintains Rani Therapeutics(RANI.US) With Buy Rating, Maintains Target Price $5 - Moomoo
CCORF Maintains Rani Therapeutics(RANI.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Rani Therapeutics Price Target Maintained With a $5.00/Share by Canaccord Genuity - Moomoo
Rani Therapeutics Is Maintained at Buy by Canaccord Genuity - Moomoo
RANI Maintained by Canaccord Genuity -- Price Target Stays at $5 - GuruFocus
Canaccord reiterates Buy on Rani Therapeutics stock, $5 target By Investing.com - Investing.com South Africa
Canaccord reiterates Buy on Rani Therapeutics stock, $5 target - Investing.com
Insiders Enjoy US$582k Return After Buying Rani Therapeutics Holdings Stock - simplywall.st
Lake Street Initiates Rani Therapeutics(RANI.US) With Buy Rating, Announces Target Price $9 - Moomoo
Rani Therapeutics CFO Sanford to depart - MSN
Nasdaq Delisting Risk Looms as Rani Therapeutics Fails to Meet $1 Minimum Bid Price - TipRanks
Rani Therapeutics Reports First Quarter 2026 Financial Results; Provides Corporate Update; Announces CFO Transition - The Manila Times
Rani Therapeutics Q1 Net Loss Narrows, Revenue Rises; CFO Svai Sanford to Step Down - Moomoo
RANI Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Rani Therapeutics | SCHEDULE 13G/A: Others - Moomoo
Rani Therapeutics reports Q1 EPS (4c), consensus (5c) - TipRanks
Rani Therapeutics Sees Funding Sufficient Into 4Q27 >RANI - Moomoo
Rani Therapeutics CFO to depart, reports Q1 results - Investing.com UK
Rani Therapeutics CFO to depart, reports Q1 results By Investing.com - Investing.com South Africa
Rani Therapeutics Holdings Inc Stock (RANI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Rani Therapeutics Holdings Inc Stock (RANI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| South Cone Investments Limited | 10% Owner |
Oct 21 '25 |
Sale |
2.77 |
4,000,000 |
11,074,000 |
2,379,194 |
| South Cone Investments Limited | 10% Owner |
Oct 20 '25 |
Sale |
2.41 |
1,923,000 |
4,637,314 |
6,379,194 |
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):